COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | |||||
---|---|---|---|---|---|---|---|
Feb. 06, 2021 |
Jul. 09, 2019 |
Jan. 31, 2021 |
Jan. 31, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Nov. 15, 2019 |
|
Net Investment Income [Line Items] | |||||||
Research and development expenses | $ 15,538,122 | $ 4,694,349 | |||||
Up-front payment | 10,000,000 | $ 10,000,000 | |||||
Payment for expenditures | $ 760,000 | $ 760,000 | |||||
Common stock received | 185,053 | ||||||
Common stock issued | 59,835 | ||||||
Common stock reserved for issuance | 17,414 | 82,237 | |||||
Compensation description | The Company had an agreement with Dr. Dybul, the Company’s Executive Vice-Chair, whereby he fulfilled the duties as prescribed by the Company’s bylaws and received annual compensation in the amount of $430,000, plus options to purchase 300,000 shares of Common Stock that vested immediately. Dr. Dybul was given a one-time grant of options to purchase 450,000 shares of Common Stock at a strike price of $8.00 per share on June 11, 2020. As of July 1, 2021, this agreement was terminated upon Dr. Dybul becoming the Company’s full-time CEO (see Note 10.) The Company has a consulting agreement for services of a Senior Medical Advisor for $210,000 per year on a part-time basis. | ||||||
G-Tech [Member] | License Agreement [Member] | |||||||
Net Investment Income [Line Items] | |||||||
Payment for license | $ 1,200,000 | $ 1,200,000 | |||||
Royalty Percentage | $ 0.02 | ||||||
Consulting Agreement [Member] | G-Tech [Member] | |||||||
Net Investment Income [Line Items] | |||||||
Consulting expenses | $ 130,000 | ||||||
Monthly consulting fee | $ 25,000 | ||||||
Research and development expenses | 275,000 | $ 1,125,000 | |||||
Monthly research costs | 144,500 | ||||||
Payment for scientific staffing resources | $ 2,409,000 | $ 1,022,000 |